Literature DB >> 28072597

Reperfusion injury in ST-segment elevation myocardial infarction: the final frontier.

Gjin Ndrepepa1, Roisin Colleran, Adnan Kastrati.   

Abstract

ST-segment elevation myocardial infarction is a major cause of morbidity and mortality worldwide. Reperfusion injury (RI) following the opening of an occluded coronary artery mitigates the effect of reperfusion by further accentuating ischemic damage and increasing infarct size. Experimental studies have shown that nearly 50% of final infarct size is attributable to RI, an elusive phenomenon that remains resistant to treatment. This review proposes a hypothesis to explain the failure of strategies that have been used in an attempt to prevent RI. This hypothesis suggests that, after a certain duration of myocardial ischemia in the affected myocardium, three phases of myocardial damage occur: reversible ischemia, irreversible ischemia, and necrosis. In the reversible ischemia phase, cellular adaptive responses remain functional, and cellular repair and thus recovery of cellular functions is possible, whereas in the irreversible ischemia phase protective maneuvers fail to confer cytoprotection. Preventive therapies for RI fail because they cannot prevent cell death once cells have entered the irreversible ischemia phase, although they may succeed in postponing cell death. Failure to salvage myocardium with irreversible ischemia in addition to postponement and change in the mode of cell death (mainly from necrosis to apoptosis) by various RI preventive strategies may be the key to understanding the failure of these strategies in the clinical setting, despite their success in the reduction of infarct size in the experimental setting. Early reperfusion before large amounts of myocardium at risk reach the stage of irreversible ischemia is the best strategy for reduction of RI-related myocardial damage.

Entities:  

Mesh:

Year:  2017        PMID: 28072597     DOI: 10.1097/MCA.0000000000000468

Source DB:  PubMed          Journal:  Coron Artery Dis        ISSN: 0954-6928            Impact factor:   1.439


  9 in total

1.  Cortical bone-derived stem cell therapy reduces apoptosis after myocardial infarction.

Authors:  Alexander R H Hobby; Thomas E Sharp; Remus M Berretta; Giulia Borghetti; Eric Feldsott; Sadia Mohsin; Steven R Houser
Journal:  Am J Physiol Heart Circ Physiol       Date:  2019-08-23       Impact factor: 4.733

2.  Comparison of the prognosis for different onset stage of cardiogenic shock secondary to ST-segment elevation myocardial infarction.

Authors:  Shuaihua Qiao; Jingmei Zhang; Zhenzhen Kong; Han Wu; Rong Gu; Hongyan Zheng; Biao Xu; Zhonghai Wei
Journal:  BMC Cardiovasc Disord       Date:  2020-06-19       Impact factor: 2.298

3.  Protective effect of dimethyl fumarate on oxidative damage and signaling in cardiomyocytes.

Authors:  Yuanyuan Kuang; Yinzhuang Zhang; Zhen Xiao; Lijun Xu; Ping Wang; Qilin Ma
Journal:  Mol Med Rep       Date:  2020-07-15       Impact factor: 2.952

4.  Optimal strategy of primary percutaneous coronary intervention for acute myocardial infarction due to unprotected left main coronary artery occlusion (OPTIMAL): study protocol for a randomised controlled trial.

Authors:  Yang Gao; Feng Zhang; Chenguang Li; Yuxiang Dai; Ji'e Yang; Ya'nan Qu; Juying Qian; Junbo Ge
Journal:  Trials       Date:  2019-03-08       Impact factor: 2.279

Review 5.  Platelets Are at the Nexus of Vascular Diseases.

Authors:  Héloïse Lebas; Katia Yahiaoui; Raphaël Martos; Yacine Boulaftali
Journal:  Front Cardiovasc Med       Date:  2019-09-11

6.  Ginkgolide B for Myocardial Ischemia/Reperfusion Injury: A Preclinical Systematic Review and Meta-Analysis.

Authors:  Peng-Chong Zhu; Qiang Tong; Zhuang Zhuang; Zi-Hao Wang; Li-Hui Deng; Guo-Qing Zheng; Yan Wang
Journal:  Front Physiol       Date:  2019-10-16       Impact factor: 4.566

7.  microRNA-130a-5p suppresses myocardial ischemia reperfusion injury by downregulating the HMGB2/NF-κB axis.

Authors:  Yong Li; Hongbo Zhang; Zhanhu Li; Xiaoju Yan; Yuan Li; Shuai Liu
Journal:  BMC Cardiovasc Disord       Date:  2021-03-03       Impact factor: 2.298

8.  Effect of Tirofiban Injection on vascular endothelial function, cardiac function and inflammatory cytokines in patients with acute myocardial infarction after emergency Percutaneous Coronary Intervention.

Authors:  Shi-Xin Kang; Xiao-Min Meng; Jing Li
Journal:  Pak J Med Sci       Date:  2022 Jan-Feb       Impact factor: 1.088

9.  Dexmedetomidine postconditioning suppresses myocardial ischemia/reperfusion injury by activating the SIRT1/mTOR axis.

Authors:  Xiong Zhang; Yongxing Li; Yong Wang; Yuerong Zhuang; Xiaojie Ren; Kai Yang; Wuhua Ma; Ming Zhong
Journal:  Biosci Rep       Date:  2020-05-29       Impact factor: 3.976

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.